Floatz logo

Nirsevimab

Respiratory Syncytial Virus (RSV)

Menzies School of Health Researchmonoclonal_antibodyPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Respiratory Syncytial Virus (RSV) cohort.

Asset / SponsorPhaseRating
Recombinant respiratory syncytial virus pre-fusion F protein antigen
Medical University of Vienna
Phase 2CCC

Same molecule, other indications

Nirsevimab is also rated in:

viral respiratory tract infectionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →